JP2010523716A - ベンゾジアゼピン受容体拮抗薬を用いるダウン症候群の治療 - Google Patents

ベンゾジアゼピン受容体拮抗薬を用いるダウン症候群の治療 Download PDF

Info

Publication number
JP2010523716A
JP2010523716A JP2010503256A JP2010503256A JP2010523716A JP 2010523716 A JP2010523716 A JP 2010523716A JP 2010503256 A JP2010503256 A JP 2010503256A JP 2010503256 A JP2010503256 A JP 2010503256A JP 2010523716 A JP2010523716 A JP 2010523716A
Authority
JP
Japan
Prior art keywords
composition
benzodiazepine
active ingredient
pharmaceutically active
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523716A5 (enExample
Inventor
ラオ，スリニバス
アンダーソン，ジェフリー，ジェイ．
クランツラー，ジェイ，ディー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2010523716A publication Critical patent/JP2010523716A/ja
Publication of JP2010523716A5 publication Critical patent/JP2010523716A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010503256A 2007-04-11 2008-04-11 ベンゾジアゼピン受容体拮抗薬を用いるダウン症候群の治療 Pending JP2010523716A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91125407P 2007-04-11 2007-04-11
PCT/US2008/060133 WO2008128116A1 (en) 2007-04-11 2008-04-11 Treatment of down syndrome with benzodiazepine receptor antagonists

Publications (2)

Publication Number Publication Date
JP2010523716A true JP2010523716A (ja) 2010-07-15
JP2010523716A5 JP2010523716A5 (enExample) 2011-05-26

Family

ID=39864354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503256A Pending JP2010523716A (ja) 2007-04-11 2008-04-11 ベンゾジアゼピン受容体拮抗薬を用いるダウン症候群の治療

Country Status (5)

Country Link
EP (1) EP2146576A4 (enExample)
JP (1) JP2010523716A (enExample)
AU (1) AU2008240148B2 (enExample)
CA (1) CA2683754A1 (enExample)
WO (1) WO2008128116A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
CN112569216B (zh) * 2019-09-30 2022-02-15 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
GB202413915D0 (en) * 2024-09-20 2024-11-06 Fitabeo Therapeutics Ltd treatment of drug use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
ES2278345T3 (es) * 2003-07-25 2007-08-01 Neurogen Corporation Imidazo-pirimidinas y triazolo-pirimidinas: ligandos de receptores de benzodiazepinas.
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013001423; Ｎｅｕｒｏｂｉｏｌｏｇｙ　ｏｆ　Ａｇｉｎｇ Ｖｏｌ．１５，Ｎｏ．１, 1994, ｐ６９-８４ *
JPN6013001426; Ｎａｔｕｒｅ　Ｎｅｕｒｏｓｃｉｅｎｃｅ ［ｏｎｌｉｎｅ］, 20070225, ｄｏｉ：１０．１０３８／ｎｎ１８６０ *
JPN6013001427; Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｔｈｅｒａｐｅｕｔ Ｖｏｌ．２８０，Ｎｏ．１, 1997, ｐ３１６-３２５ *
JPN6013001429; Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｔｈｅｒａｐｅｕｔ Ｖｏｌ．２６６，Ｎｏ．２, 1993, ｐ１０１８-１０２８ *

Also Published As

Publication number Publication date
CA2683754A1 (en) 2008-10-23
AU2008240148A1 (en) 2008-10-23
WO2008128116A1 (en) 2008-10-23
AU2008240148B2 (en) 2012-09-27
EP2146576A4 (en) 2013-01-16
EP2146576A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
ES2610508T3 (es) Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
BRPI0712994A2 (pt) uso de derivados de alfa-aminoamida úteis no tratamento de distúrbios cognitivos
AU2019280980B2 (en) Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US20190105308A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
US20180092890A1 (en) Nootropic compositions for improving memory performance
JP3823194B2 (ja) ５ｈｔ▲３▼拮抗剤の新規医薬用途
KR20140146217A (ko) 파킨슨병을 치료하는 방법
US10357486B2 (en) Treatment of cognitive impairment with PDE4 inhibitor
AU2018383098A1 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
JPH0227327B2 (enExample)
AU2008240148B2 (en) Treatment of down syndrome with benzodiazepine receptor antagonists
US20090270373A1 (en) Treatment of down syndrom with benzodiazepine receptor antagonists
JP6738797B2 (ja) レット症候群治療薬
AU2014307802A1 (en) Treatment of cognitive impairment with combination therapy
HK40012437A (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
JP2003221337A (ja) 酢酸アミド誘導体を有効成分とする痴呆症治療剤
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease
HK1184674A (en) Treatment for neurological and mental disorders
HK1184674B (en) Treatment for neurological and mental disorders
HK1158065A (en) Treatment for neurological and mental disorders

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702